Results 191 to 200 of about 63,127 (238)

Late Pulmonary and Lymph Node Recurrence 14 Years after Curative Resection of Incidentally Diagnosed Appendiceal Adenocarcinoma with Hepatic Metastasis. [PDF]

Surg Case Rep
Nishina K, Yamaguchi T, Furukawa M, Kitani Y, Nakane K, Koseki T, Kawasaki K, Takahashi M, Inada K.   +8 more
europepmc   +1 more source

Deep Learning Predicts Imminent Tumor Progression in Advanced Pancreatic Adenocarcinoma Using Serial CT Scans During Chemotherapy

MedComm, Volume 7, Issue 8, August 2026.
A spatiotemporal deep learning model combining serial CT scans and baseline clinical data predicts tumor progression at the next follow‐up visit in advanced PDAC. The model achieved robust performance across internal, external, and prospective cohorts (AUC: 0.74–0.77). This noninvasive approach enables earlier identification of imminent progression and
Jun Cheng, Yize Mao, Shuxiang Huang, Xiaotong Tan, Xiaoping Yi, Xiaoying Du, Qiulin Liu, Jianyao Zhou, Rong Huang, Weijie Chen, Rong Zhang, Lizhi Liu, Wufeng Xue, Ruobing Huang, Youhui Qian, Dong Ni, Wenjun Mao, Tao Qin, Shengping Li, Qiuxia Yang   +19 more
wiley   +1 more source

Combined intervention of <i>Akkermansia muciniphila</i> and sodium butyrate ameliorates oxaliplatin-induced peripheral neuropathy by suppressing neuroinflammation and reducing serum neurofilament light chain. [PDF]

Front Immunol
Xu D, Fu D, Chen J, Hu Q, Wang Y, Wu J.
europepmc   +1 more source

Oxaliplatin-induced cardiotoxicity in mice is connected to the changes in energy metabolism in the heart tissue. [PDF]

Cardiooncology
Du J, Sudlow LC, Shahverdi K, Zhou H, Michie MS, Schindler TH, Mitchell JD, Mollah S, Berezin MY.   +8 more
europepmc   +1 more source

Chemotherapy-derived DAMPs drive reprogramming of tumor-associated macrophages toward a pro-inflammatory phenotype in hepatocellular carcinoma. [PDF]

Sci Rep
Songjang W, Paiyabhroma N, Srisuwan C, Promchai S, Nensat C, Pankhong P, Kumphune S, Jiraviriyakul A.   +7 more
europepmc   +1 more source

Lineage-Specific Disruption of Hematopoiesis by Oxaliplatin: Mechanisms of Erythropoietin Resistance and Immune Suppression. [PDF]

J Hematol Oncol Res
Sudlow LC, Du J, Shahverdi K, Zhou H, Berezin MY.   +4 more
europepmc   +1 more source

Impact of <i>UGT1A1*28</i> polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. [PDF]

Future Oncol
Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A.   +10 more
europepmc   +1 more source

DRG Explant Model for Understanding Mechanism of Oxaliplatin-Induced Peripheral Neuropathy and Identifying Potential Therapeutic Targets. [PDF]

Antioxidants (Basel)
Du J, Sudlow LC, Luzhansky ID, Berezin MY.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Oxaliplatin

Clinical Pharmacokinetics, 2000
Oxaliplatin is the first clinically available diaminocyclohexane platinum coordination complex. The drug is non-cross-resistant with cisplatin or carboplatin and is one of the few active drugs against human colorectal cancer. Its cytotoxicity is synergistic with fluorouracil and folinic acid (leucovorin), the reference treatment for this disease.
F, Lévi, G, Metzger, C, Massari, G, Milano   +3 more
openaire   +2 more sources